Pay in 4 interest-free payments of $6.36 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Key Summary The patent for semaglutide will expire in 10 countries this year, but the UK patent will remain till 2031
Additional important safety considerations include: Risk of hypoglycaemia when combined with insulin or sulfonylureas Potential for dehydration and acute kidney injury from severe gastrointestinal symptoms Increased risk of diabetic retinopathy complications with rapid glucose lowering, particularly with semaglutide Importantly, memory loss or cognitive impairment is not listed among the recognised adverse effects in the Summary of Product Characteristics (SmPC) for any GLP-1 receptor agonist licensed in the UK
Merrifield, R
Love the product but wish it wasnt so expensive I have a lot more energy I havent seen any weight loss but I feel its coming
Together, these findings suggest a diversion of glucose flux away from glycolysis at this critical branch point in the pathway
A direct phase 3 comparison is underway and will provide more meaningful evidence
